July 17, 2017

Update from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June 2017

In June, Lung Foundation Australia staff members attended the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The meeting was packed with new data, clinical trial results, meet the professor/expert and educational sessions covering lung cancer and mesothelioma.

Presentations focused on many studies utilising new targeted therapies for Non Small Cell Lung Cancer (NSCLC) including for EGFR, Alk and B-Raf positive mutations. In addition, studies using the various immunotherapy therapies in NSCLC in the first-line and subsequent lines of therapy were presented. This means there will be increased options for people with NSCLC and hopefully better outcomes.

The challenge will be in understanding the best sequence and/or combinations for the various therapies in the specific NSCLC subtypes.

Small Cell Lung Cancer (SCLC) also featured at the meeting with immunotherapy, maintenance therapy and standard of care with the addition of novel agents methods being looked at to improve outcomes for patients with SCLC.

Mesothelioma was also discussed and ASCO expert Michael Sabel, MD noted that “mesothelioma is a very difficult cancer to treat, and has very poor success rates with chemotherapy.” However, immunotherapy may offer new options as a second-line treatment. Another study for mesothelioma patients looked at standard of care chemotherapy with the addition of nintedanib versus standard of care chemotherapy with the addition of placebo.

Another presentation discussed research suggesting improvements in cancer-related fatigue from yoga were linked to improvements in sleep quality and daytime dysfunction. Patients were taught physical alignment postures as well as breathing and mindfulness exercises and results showed those participating in the yoga had improved cancer-related fatigue.

For more information about these studies or medicines, please talk to your health professional or members of your multidisciplinary team. Please note: some of these products may not be available, registered or reimbursed in Australia.